Vincent Ribrag

14PUBLICATIONS
92CO-AUTHORS
Haematological tumoursLiquid biopsiesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Feb 18, 2026
Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Manali Kamdar, Scott R Solomon, Jon E Arnason

|Dec 22, 2025
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin

|Sep 24, 2025
CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis.

Myriam Ben Khelil, Ahmadreza Arbab, Janesa Srikanthan

|Mar 03, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Vincent Camus, Thierry Molina, Fabienne Desmots

|Nov 12, 2024
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.

Won Seog Kim, Jake Shortt, Pier Luigi Zinzani

Pageof 3